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In late December 2019, a number of 27 people with clinical symptoms of dry cough, dyspnea, fever, and bilateral lung infiltrates on imaging with an unknown cause were diagnosed in Wuhan, Hubei Province, China. A few days later, a new virus of great global public health concern was isolated and designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), later referred to as coronavirus disease 2019 (COVID-19) (Chen et al. [@CR14]). This new virus was found to be highly contagious and quickly spread globally, leading the World Health Organization (WHO) to officially declare the COVID-19 outbreak a global pandemic on March 11, 2020 (Mahase [@CR62]). As an emerging acute respiratory infectious disease, clinical symptoms are characterized predominantly by fever and dry cough followed by dyspnea, bilateral infiltrates, sputum production, haemoptysis, lymphopenia, shortness of breath, sore throat, and neurological and gastrointestinal manifestations (Huang et al. [@CR40]; Wang et al. [@CR110], [@CR111]). COVID-19 employs cell receptor angiotensin-converting enzyme 2 (ACE2) for host cell entry (Xu et al. [@CR116], [@CR118]; Zhou et al. [@CR125], [@CR126]), which is present in the type II alveolar cells (Zou et al. [@CR127]), enterocytes from ileum and colon (Xiao et al. [@CR115]), liver cholangiocytes (Qi et al. [@CR80]), aqueous humor (Holappa et al. [@CR39]), myocardial cells (Donoghue et al. [@CR22]), proximal tubule kidney cells (Zou et al. [@CR127]), urothelial bladder cells (Zou et al. [@CR127]), epithelial cells of the oral mucosa (Xu et al. [@CR116], [@CR118]), as well as neurons and glia in the brain stem and particular cerebral regions (Xia and Lazartigues [@CR113]). The high expression and wide distribution of ACE2 receptor in human body may sustain the ubiquitous potential infection of COVID-19 and explain its tropism. It is also recognized that COVID-19 could be transmitted via multiple routes, predominantly binding to ACE2 alveolar epithelial cells (Wan et al. [@CR109]; Zhou et al. [@CR125], [@CR126]) or by oral-fecal transmission (Gu et al. [@CR34]), among others. To date, it is accepted that the incubation period of COVID-19 is up to 14 days, although it has been suggested that it may be extended up to 24 days, which possibly reflects a double exposure. Furthermore, asymptomatic infection has been additionally reported (Huang et al. [@CR40]; Linton et al. [@CR55]). Interestingly, previous studies showed that the coronavirus also infects the central nervous system (CNS) (Arbour et al. [@CR7]; Lau et al. [@CR51]) since it can spread from the respiratory tract to the CNS, showing neuroinvasive capacities.

There is uncertainty about extra-pulmonary manifestations of COVID-19, including those affecting the CNS. Numerous efforts to implement effective therapeutic strategies are underway. The distressing scenario that the world is experiencing regarding COVID-19 calls for new treatment approaches and, in this respect, we want to emphasize the advantages of melatonin (*N*-acetyl-5-methoxytryptamine) as a potential therapeutic agent to ameliorate the CNS damage associated with SARS-CoV-2′s disease. Melatonin is not a molecule addressed to diminish the viral load nor target specific enzymes involved in viral replication and transcription, nevertheless it has multiple indirect antiviral actions (Anderson et al. [@CR5]; Elmahallawy et al. [@CR24]; Junaid et al. [@CR44]; Montiel et al. [@CR66]; Tan et al. [@CR103]). In this regard, some recent reviews have suggested the utility of melatonin as adjunctive or even regular therapy for COVID-19 patients who suffer pneumonia, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (Tan and Hardeland [@CR101]; Zhang et al. [@CR123]), as well as extra-respiratory complications (Dominguez-Rodriguez et al. [@CR21]; Shneider et al. [@CR94]). Regarding the experimental clinical use of melatonin in the current critical situation, it is important to highlight that melatonin is not only a well-known anti-inflammatory (Carrascal et al. [@CR11]), antioxidative (Rodriguez et al. [@CR90]), and immune-enhancing agent (Carrillo-Vico et al. [@CR12]) but also a molecule with a high safety profile (Seabra et al. [@CR93]). Its small size and amphiphilic nature allow melatonin high cell diffusion capability and it has high permeability through biological compartments, including blood brain barrier (BBB) (Tarocco et al. [@CR105]), reaching cytosolic, mitochondrial, and nuclear compartments (Menendez-Pelaez and Reiter [@CR65]; Reiter et al. [@CR87]). BBB integrity is crucial for the maintenance of CNS, and thus, several neurological disorders debut after deterioration of the BBB (Rosenberg [@CR91]). Melatonin restores BBB homeostasis limiting microvascular hyperpermeability (Alluri et al. [@CR1]; Liu et al. [@CR59]) and therefore making it a promising candidate against neuroinvasion caused by COVID-19. In view of all the above information, this review focuses on characteristics, mechanisms, and implications of CNS involvement caused by SARS-CoV-2 infection, in which we speculate on how the use of the melatonin could become the basis for a possible neurotherapeutic approach.

How Does SARS-CoV-2 Neuroinvasiveness Occur? Melatonin Potential to Respond to COVID-19 Neuropathogenesis {#Sec2}
=========================================================================================================

SARS-CoV-2 shares its clinical symptoms with those described for SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV) betacoronaviruses. Previously, it has been reported the presence of SARS‐CoV and MERS-CoV particles in the brain of experimental animal models and patients (Ding et al. [@CR20]; Li et al. [@CR53]; Xu et al. [@CR117]). However, regarding SARS‐CoV‐2, two important questions that arise are as follows: (i) The exact route by which the virus enters the CNS and (ii) whether its presence may be detected in the cerebrospinal fluid (CSF) or postmortem tissue specimens collected from COVID-19 victims. It is known that human coronaviruses can penetrate the CNS through different routes, directly from the external environment affecting the olfactory nerve and olfactory bulb neuroepithelium or using either the lymphatic or the hematogenous route, which represents an excellent opportunity to infect endothelial cells of the BBB (Desforges et al. [@CR18]). It has been recently reported that human ACE2 receptors are the gateway for SARS-CoV-2 and that transmembrane protease serine 2 (TMPRSS2) is essential for the SARS-CoV-2´s spike (S) protein activation, which facilitates viral attachment to the surface of target cells (Hoffmann et al. [@CR38]). Consequently, it can be thought that those brain regions with the highest expression of ACE2 receptors could turn out to be more affected by SARS-CoV-2 infection, although the involvement of other receptors or co-receptors is not definitely discarded. In this context, a recent study using mRNA expression levels data provided by the Allen Human Brain Atlas has demonstrated ACE2 in brain regions, such as the olfactory bulb (OB) (Lapina et al. [@CR50]). This may explain the neuropathogenic impact of SARS-CoV-2 on the partial loss of the sense of smell or total anosmia, as a result of nasal inflammation, mucosal edema, and obstruction of airflow into the olfactory cleft. Additionally, the analyses of three databases have shown high expression levels of human ACE2 in several regions of the brain (e.g., substantia nigra) and both neurons and astrocytes, which would help us to understand how SARS-CoV-2 can spread into the brain and cause neurological damage (Chen et al. [@CR15]) (Fig. [1](#Fig1){ref-type="fig"}). Conversely, OB imaging by magnetic resonance was found normal in a COVID-19 patient with anosmia and without intensity signals of nasal congestion in the early phase of the disease (Galougahi et al. [@CR30]); even though, anosmia may persist for a long time. Another essential point for initial viral neuroinvasion is the recent announcement by genome sequencing of the first reported case of SARS-CoV-2 in the CSF (Xiang [@CR114]). Additionally, a recent case study reporting viral particles in endothelial cells and frontal lobe sections obtained at forensic examination confirmed the presence of SARS-CoV-2 in neural tissue (Paniz-Mondolfi et al. [@CR75]). After these observations, brain infection is being seriously considered by the scientific community because important pathologies at neurological level are emerging associated with COVID-19 patients; encephalopathy (Filatov et al. [@CR27]; Poyiadji et al. [@CR78]), meningitis/encephalitis (Moriguchi et al. [@CR67]; Ye et al. [@CR120]), Guillain-Barré syndrome (Zhao et al. [@CR124]), cerebrovascular disease (Helms et al. [@CR37]; Wu et al. [@CR112]; Zhai et al. [@CR122]) and epilepsy (Karimi et al. [@CR47]). Moreover, Li and colleagues (Li et al. [@CR54]) have hypothesized that the ability of SARS-CoV-2 targeting the CNS may, at least in part, explain the acute respiratory failure of COVID-19 patients. Conversely, it has also been argued that the brain dysfunction induced by SARS-CoV-2 still lacks strong evidence and, therefore, this relevant question should be further investigated.Fig. 1The nasal cavity could be the gateway of SARS-CoV-2 to reach directly the central nervous system through affecting the olfactory nerve and olfactory bulb neuroepithelium. Once in the brain, SARS-CoV-2 would initiate the innate immune responses at early stages of the COVID-19 resulting in neurological disorders. At this point, high doses of melatonin may exert anti-inflammatory effects and act as a buffer against enhanced immunoreactivity, which would reduce the neuropathogenesis of SARS-CoV-2 infection

Taken together, the abovementioned evidence indicates that counteracting or mitigating the neuroinvasion of SARS-CoV-2 emerges as an essential strategy to prevent or treat COVID-19. At this point is where melatonin can act as a protective agent against virus-related diseases (Anderson and Reiter [@CR6]; Elmahallawy et al. [@CR24]; Silvestri and Rossi [@CR96]; Tan et al. [@CR103]) and several pathologies of CNS (Brigo et al. [@CR9]; Farez et al. [@CR26]; Gerber et al. [@CR32]; Ramos et al. [@CR83]) including those affecting BBB (Ramos et al. [@CR83]) (Fig. [1](#Fig1){ref-type="fig"}). Regardless, it is possible that melatonin may act inside the neural cells targeted by SARS-CoV-2. Its amphiphilic nature helps it to reach intracellular organelles, binding to mitochondrial and cell cytosol proteins, thus increasing its neural availability (Tan [@CR102]) and therapeutic versatility in at least three different ways. Firstly, melatonin binds to calmodulin (CaM) and may act on the Ca^2+^/calmodulin-dependent protein kinase II (Ca^2+^/CaMKII) system, thereby regulating the expression of ACE2 (Lambert et al. [@CR49]). Secondly, CaMKII has been found to copurify with proteasomes of the brain (Bingol et al. [@CR8]) and the ubiquitin--proteasome system is involved in the early viral replicative cycle. Interestingly, like a proteasome inhibitor (Vriend and Reiter [@CR108]), melatonin may regulate several events involved in proteostasis, through the Ca^2+^/CaMKII system, which can also influence SARS-CoV-2 infectivity. Thirdly, given its tectonic impact in host cell homeostasis, it is expected that SARS-CoV-2 dysregulates mitochondrial metabolism. In this regard, it is worth noting that many of the actions displayed by melatonin are directed to maintain mitochondrial function (Tan and Reiter [@CR104]). Particularly with respect to neuronal damage, the neuroprotection provided by melatonin has been revealed to be mediated by the high-affinity melatonin receptors hosted in the mitochondria (Tan and Reiter [@CR104]). Therefore, any decrease of melatonin (pineal or mitochondrial) levels may open a way for increasing the viral control of cellular metabolism and thus speeding up the replication of SARS-CoV-2 and severity of many viral infections (Anderson and Reiter [@CR6]).

About 10--15% of the COVID-19 patients with ARDS and organ failure have been associated with the commonly known as hyperinflammation or "cytokine storm syndrome". The question that arises is; might SARS-CoV-2 infection trigger a cytokine storm in the brain? In light of recent COVID-19-associated case reports describing a rare form of severe brain damage with hemophagocytic lymphohistiocytosis (HLH) (Radmanesh et al. [@CR81]), and a patient with an acute necrotizing hemorrhagic encephalopathy (Poyiadji et al. [@CR78]), it should be considered that COVID-19 infection may induce a "cytokine storm syndrome" in the brain (Mehta et al. [@CR64]), deserving special consideration and further research. In agreement with the above, it has also been reported that upregulation of pro-inflammatory mediators and a deregulated immune response can be useful predictors of lethality by COVID-19 (Ruan et al. [@CR92]). Therefore, a plethora of alterations at interconnected signaling pathways, such as the mammalian target of rapamycin (mTOR) (Zhou et al. [@CR125], [@CR126]), sirtuins (SIRTs) (Anderson and Reiter [@CR6]), NLRP3 inflammasome (Deftereos et al. [@CR17]), Toll Like Receptors (TLRs) (Conti et al. [@CR16]) or single-pass type I transmembrane receptor (Notch) (Rizzo et al. [@CR89]) are key factors that may modulate COVID-19-related cellular and molecular events (Fig. [2](#Fig2){ref-type="fig"}). In this context, as an universal regulator targeting a large number of different signaling pathways and physiological processes, melatonin may exerts a significant neuroimmunomodulatory protection against viral infections (Liu et al. [@CR58]; Ma et al. [@CR61]; Shukla et al. [@CR95]; Tiong et al. [@CR106]; Xu et al. [@CR119]). Consequently, the capacity of the indoleamine for counteracting the neuroinvasion by SARS‐CoV‐2 infection cannot be underestimated, nor neglected and unquestionably it requires further research.Fig. 2Hypothetical diagram of the possible targets where melatonin may act against SARS-CoV-2 infection in the CNS. SARS-CoV-2 enters neuronal cells through ACE2, as the receptor binding domain, and TMPRSS2 for spike protein (s protein) priming. Next, SARS-CoV-2 nucleocapsid triggers clathrin-mediated endocytosis enhancing cytoplasm release. Subsequently, the single negative strand RNA \[( −)gRNA\] synthesized from ( +)gRNA template is used to replicate more copies of viral RNAs. Afterwards, subgenomic RNAs (sgRNAs) synthesized from the ( +)gRNA template encode viral structural and accessory proteins, which are subsequently assembled with newly synthesized viral RNAs in the ER and Golgi, followed by budding into the lumen of the ERGIC to form new virions. Then, virus particles are transported in secretory vesicles to the plasma membrane and released by exocytosis. Furthermore, the entry of SARS-CoV-2 into neuronal cells may dysregulate mitochondrial metabolism increasing ROS and leading to the induction of endoplasmic reticulum stress. In this regard, melatonin\'s high diffusibility allows it to enter in neuronal cells, it binds to CaM and may act on the Ca^2+^/CaMKII system, regulating the expression of ACE2, modulating the linking between endoplasmic reticulum stress and inflammatory response and scavenging ROS. However, in both MT1/MT2 and α7nAChR receptors, melatonin-mediated signaling may influence in reduced SARS-CoV-2 entry. When SARS-CoV-2 infects the CNS, it triggers the release of pro-inflammatory cytokines. (i) TNF-α, which acts by binding to TNFR receptor recruiting TRADD. This protein binds to TRAF2 to phosphorylate and activate the IKK. Then, IKK complex phosphorylates IKBα, resulting in the translocation of NF-κB to the nucleus, where it targets many coding genes for mediators of inflammatory responses. (ii) IL-6 induces gene activation in response to cytokine receptor stimulation. STAT3 proteins dimerize and translocate to the nucleus. JAK2/STAT3 signaling is a crucial link acting as a pivotal mediator of neuroinflammation. (iii) The binding of SARS-CoV-2 to the TLR (TLR3/7/9) upregulates the pro-inflammatory transcription factor NF-κB and causes the release of pro-IL-1β which is cleaved by caspase-1, followed by NLRP3 inflammasome activation. Consequently, melatonin may revert these pro-inflammatory effects by inhibiting the JAK2/STAT3 signaling pathway and NF-κB translocation. In addition, as an anti-inflammatory agent, melatonin inhibits the activation of NLRP3 inflammasome. Stimulation (blue colored) or inhibition (red colored) by melatonin and SARS-CoV-2 are also shown. Organelles/structures were not drawn to scale

Melatonin Receptors in the Context of CNS Involvement for SARS-CoV-2 {#Sec3}
====================================================================

Given the astonishing pleiotropy of melatonin, it may be expected that cellular and molecular mechanisms by which this indoleamine mediates neuroprotection would be complex as well. To a some extent the biological effects of melatonin are mediated through the interaction with two high-affinity G protein-coupled receptors, MT1 and MT2, which are involved in multiple signaling cascades of cell protection and survival (Liu et al. [@CR57]). Both in the CNS and peripheral organs melatonin receptors are ubiquitously distributed (Ekmekcioglu [@CR23]; Ng et al. [@CR69]). Unfortunately, we must assume our current ignorance of the mechanisms by which MT1 and MT2 may influence melatonin-mediated signaling in the brain of patients afflicted by COVID-19. However, melatonin receptor‐mediated protection has been suggested against the lethal viral diseases such as the Venezuelan equine encephalomyelitis (VEE) virus (Valero et al. [@CR107]) as well as in the improvement of antioxidative defense system against respiratory syncytial virus (RSV) (Huang et al. [@CR41]).

It has been reported that 1/3 patients with confirmed COVID-19 present acute cerebrovascular disease and epilepsy, among other neurological symptoms (Jin et al. [@CR43]; Mao et al. [@CR63]). It is also known that COVID-19 patients might develop a "cytokine storm syndrome" due to an exacerbated level of pro-inflammatory biomarkers which contribute to significantly increase the risk of ischemic stroke. In this regard, SARS-CoV-2 may enter the CNS via the haematogenous diffusion and infect the endothelial cells of the BBB. It is important to note that melatonin may elicit part of its neuroprotective effect through melatonin receptors, and in this context MT2 upregulation would not only preserve BBB integrity but also attenuate the activation of astrocytes and microglia (Lee et al. [@CR52]). Indeed, downregulation of the hippocampal MT2 receptor has been shown to confer protection against seizures and also exhibited the anticonvulsant activity of melatonin (Stewart and Leung [@CR99]). Additionally, T lymphocytes seem to be more vulnerable against SARS-CoV-2 infection through S protein and CD147 (Wang et al. [@CR110], [@CR111]), an extracellular matrix metalloproteinase that induces the pro-inflammatory cytokine cyclophilin A, secreted by monocytes/macrophages and endothelial cells. T lymphocytes express both melatonin receptors, MT1 and MT2 (Pozo et al. [@CR79]; Slominski et al. [@CR97]), and hence, in the infected T cells melatonin may regulate the immunostimulatory activity mediated by MT1 and MT2 and block cyclophilin A/CD147 signaling pathway (Su et al. [@CR100]). For these reasons, in the search for new pharmacological strategies against COVID-19, we focused our attention on the exogenous supplementation with melatonin to preserve the immune response and counteract the neuroinflammation through its widely distributed receptors in the CNS and most of the immune cells.

Understanding of COVID-19′s Long-Term Impact on the CNS and the Influence of Melatonin as a Preventive Agent {#Sec4}
============================================================================================================

All countries are suffering the scourge of COVID-19. Unfortunately, science is still learning the natural history and pathogenicity of this emerging coronavirus as well as its immediate and devastating effects on human health. We should ask ourselves, what will be the long-term consequences of COVID-19? Lippi and co-workers (Lippi et al. [@CR56]) have proposed the possibility that months or years after infection several tissues, including the brain, patients may suffer an accelerated aging, which could manifest in neurodegenerative disorders such as Parkinson disease. Something that seems epidemiologically proven is that the most susceptible people to SARS-CoV-2 infection are the middle-aged and elderly. Based on this clinical evidence, we hypothesize that, at least partially, the progressive melatonin decline with age may account for the apparent increased COVID-19 sensitivity over life-span and specially in the elderly. As a consequence of aging, the pineal gland accumulates calcium deposits and both serum and CSF melatonin release decreases (Reiter et al. [@CR85], [@CR88]), which is being increasingly related with numerous dysfunctions and pathophysiological changes (Karasek [@CR46]). The involvement of melatonin in the context of neurodegeneration is promising since it has been well documented to counteract most of the physiopathological events that trigger neurodegenerative disorders (Ramos et al. [@CR82]). Interestingly, a certain relationship between nicotinic acetylcholine receptors (nAChRs) and infectivity by SARS-CoV-2 is suspected. However, this raises the controversy about whether it is a facilitating effect because nicotine would promote SARS-CoV-2 cell penetration through nAChRs upregulation (nAChRs) (Kabbani and Olds [@CR45]) or the opposite by the low prevalence of smokers among COVID-19 people in China (Guan et al. [@CR35]) or the hypothesized competition of nicotine and SARS-CoV-2 for binding nAChR (Changeux et al. [@CR13]). Thereby, a putative role of nAChRs in the modulation of ACE2 has been suggested at cardiovascular level (Oakes et al. [@CR73]) and presently it should be considered a possible interplay between both ACE2 and overexpressed nAChRs in the context of the SARS-CoV-2 neurotropism and neuroinfection. At this point, melatonin becomes relevant by the modulation of neuroinflammation (Niranjan et al. [@CR71]) and oxidative stress (Parada et al. [@CR76]) through the alpha 7 acetylcholine nicotinic receptor (α7nAChR), which oligomers are among the most frequent in the brain (Gotti and Clementi [@CR33]) and mediate many of the beneficial actions of the indoleamine including mitochondrial regulation. It is also noteworthy that the COVID-19 may impact on the neurotransmission process. Using a multiexperiment matrix Nataf (Nataf [@CR68]) has shown a significant co-expression of ACE2 and Dopa Decarboxylase (DDC), which may explain that any SARS‐CoV-2‐induced downregulation of ACE2 expression, previously reported for SARS-CoV (Kuba et al. [@CR48]), might disrupt the dopamine and serotonin synthesis pathway. Subsequently, the depletion of these neurotransmitters in blood and brain may reduce the serotonin-dependent melatonin availability. However, this hypothesis should be corroborated and correlated in COVID-19 patients affected by generalized anxiety disorder and depressive symptoms (Huang and Zhao [@CR42]).

Melatonin Supplementation Against SARS-CoV-2 Neurotropism: Dosage and Safety {#Sec5}
============================================================================

To our knowledge, some clinical trials of melatonin in COVID-19 that are currently underway have recently been authorized. Among them, the trial EudraCT: 2020-001808-42 has been just approved by the Spanish Agency of Medicines and Medical Devices (AEMPS [@CR98]), trying to identify the doses of melatonin that can be effective in treating the disease. The study is a phase II, single-center, double-blind, randomized placebo-controlled trial, with the objective to address the efficacy and safety of intravenous melatonin administration in ICU patients suffering from COVID-19. Likewise, the State University of New York at Buffalo is sponsoring "Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 (COVID-19)", a pilot randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin in outpatient adult patients suspected to be afflicted with COVID-19. Another example of an interventional clinical trial is provided by Brazil, one of the countries most dramatically hit by the pandemic. The Associação Fundo de Incentivo à Pesquisa is carrying out the trial "Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19" to reduce the lung burden of COVID-19 testing the efficacy of melatonin agonist ramelteon in hospitalized patients.

Nevertheless, determining the safety and the precise doses of this molecule to prescribe are challenges still to be fulfilled. When orally administered, melatonin has a low and variable bioavailability ranging into 3--33% (Andersen et al. [@CR4]; Di et al. [@CR19]; Harpsoe et al. [@CR36]). Moreover, brain is the organ where melatonin reaches lower concentration after its administration, which could justify the use of higher doses to counteract the neuroinvasive potential of SARS-CoV-2 (Andersen et al. [@CR3]). In this regard, a new melatonin galenic formulation with a higher bioavailability and faster absorption through the CNS would be required, such as intravenous (IV) (Peschechera and Veronesi [@CR77]) or intranasal administration (García-García et al. [@CR31]; Zetner et al. [@CR121]).

Even though there are not sufficient short- or long-term studies with exogenous melatonin focused on clarifying clinical safety (Seabra et al. [@CR93]), a significant number of studies and clinical trials indicated that the melatonin is safe, even at doses 100 times higher than physiological concentrations (Andersen et al. [@CR2], [@CR3]; Brzezinski [@CR10]; Nickkholgh et al. [@CR70]; Seabra et al. [@CR93]). Then, what are the recommended melatonin dosing regimens in COVID-19 patients? The answer would depend on the administration route and formulation. Reiter et al. (Reiter et al. [@CR86]) have recently proposed a dose of 40 mg/day orally to control the spread of the disease. In this regard, we hypothesized for COVID-19 patients in hyperinflammation phase an oral dose of 100 mg/day or that at least 1 mg/kg b.w would be required to establish whether melatonin inhibits the neuro-impact of SARS-CoV-2, especially among patients with severe neurological pathologies. However, the authors are not unaware of some potential risks reported for low/medium doses of this indoleamine, as has been the case in a few patients with coronary artery disease receiving 5 mg of melatonin before bedtime for a few weeks or months, who developed non-optimal arterial hypertension side effects (Rechciński et al. [@CR84]), perhaps due to hormone interference with antihypertensive pharmacotherapy (Lusardi et al. [@CR60]). These potential risks must be carefully warned considering that individuals affected by previous cardiovascular comorbidity often develop particularly acute and life-threatening forms of COVID-19 (Nishiga et al. [@CR72]). Also, worth mentioning in order to schedule melatonin with null risk is to attend its possible synergy with other hypnotic-sedative pharmacopoeia, as short-term potentiation has been described for melatonin (2 mg) and zolpidem co-administration (Otmani et al. [@CR74]) or other Z-drugs (Frisher et al. [@CR29]). However, the reported adverse side effects of oral melatonin have been minor, sporadic of easy clinical management (Foley and Steel [@CR28]). Melatonin co-administration with other drugs is also an attractive strategy to improve the management of patients with COVID-19 and reducing the possible drug side effects. Accordingly, the potential of melatonin as an adjuvant treatment (Zhang et al. [@CR123]), as well as its combination with mercaptopurine (Zhou et al. [@CR125], [@CR126]) and other therapy protocols (El-Missiry et al. [@CR25]) had been suggested as a feasible therapy against SARS-CoV-2.

Since the effective vaccine and antiviral drugs are still unavailable, it is critically important to look for an alternative strategy for COVID-19 treatment. To this aim, melatonin is a serious candidate to consider because it shows a low toxicity risk and the pharmacological efficacy needed for the preventive treatment of COVID-19 infection. Moreover, neurophysiological actions from which the clinical management and outcome of COVID-19 patients could benefit. It is time, therefore, to translate the therapeutic capacities of melatonin for the improvement of clinical practice and protection of public health in the current COVID-19 outbreak.

Concluding Remarks {#Sec6}
==================

The current SARS-CoV-2 pandemic has stressed the public health systems until unprecedented limits. The socio-economic consequences are expected to be terrible worldwide and, most important, a health threat has spread across the planet. Faced with this panorama, people are reacting with panic to SARS-CoV-2 infection since several issues have to be solving. (i) The mechanisms associated with the infectiousness of SARS-CoV-2 are not clear and their elucidation is urgently needed. (ii) SARS-CoV-2 causes different symptoms in different people and a biological explanation is lacking. (iii) Clinicians are still unsure whether people infected with COVID-19 can be reinfected. (iv) The lack of effective vaccines and specific antiviral drugs targeted at SARS-CoV-2 makes COVID-19 difficult for treating and controlling the pandemic. And (v) what will the long-term health consequences of affected COVID-19 patients be? Given the current scenario of such an uncertain future facing us at the present time, we emphasize that further investigation in the treatment with melatonin is urgently required, as well as that clinical trials are strongly needed for the best understanding of the impact of its administration in patients affected by COVID-19.
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